SUBSCRIBE
SUBSCRIBE

Odyssey Therapeutics

NEWS
Business
Top Life Sciences Startups to Watch in 2023
BioSpace is proud to present its NextGen Bio “Class of 2023,” a list of the hottest recently launched life sciences companies in North America.
December 5, 2022
 · 
15 min read
 · 
BioSpace Editorial Staff
Business
Movers & Shakers: Odyssey, Daiichi Sankyo, Atsena and More
While Biogen and Seagen made the biggest C-suite splashes this week, other companies across the biopharma industry also bolstered their leadership teams with new talent.
November 10, 2022
 · 
6 min read
 · 
Alex Keown
Odyssey Founder and CEO Gary D. Glick/Courtesy Ody
Business
Odyssey Bags $168M to Accelerate Push to the Clinic
Odyssey Therapeutics raised $168 million in a Series B financing round, which will be used to advance its portfolio of immunomodulators and oncology therapies.
October 13, 2022
 · 
3 min read
 · 
Alex Keown
Genetown
Odyssey to Aim $218 Million at Novel Targets
Odyssey Therapeutics completed an oversubscribed $218 million Series A round. The funds will be used to advance multiple programs from its pipeline and its discovery platform.
December 7, 2021
 · 
3 min read
 · 
Mark Terry
AWARDS
  • NextGen Class of 2023
JOBS
IN THE PRESS
Press Releases
Odyssey Therapeutics and Terray Therapeutics Enter Strategic Collaboration to Jointly Discover and Develop First-in-Class Transcription Factor Therapies
October 28, 2024
 · 
4 min read
Press Releases
Odyssey Therapeutics to Present New Data on its Clinical-Stage RIPK2 Scaffolding Inhibitor, OD-07656, at the American College of Gastroenterology (ACG) Annual Scientific Meeting 2024
October 28, 2024
 · 
3 min read
Press Releases
Odyssey Therapeutics Appoints Biopharma Veterans Timothy P. Walbert and Ian F. Smith to its Board of Directors
October 2, 2024
 · 
3 min read
News
Odyssey Therapeutics Announces Formation of Scientific Advisory Board
September 27, 2024
 · 
6 min read
Business
Odyssey Therapeutics Announces Strategic Collaboration to Advance AI-Driven Small Molecule Drug Discovery
April 4, 2024
 · 
2 min read
Business
Odyssey Therapeutics Appoints Julie Clauss as Chief Operating Officer and Christopher Butler as SVP, Head of Chemistry
April 2, 2024
 · 
3 min read
Genetown
Odyssey Therapeutics Announces $101 Million Series C Financing
December 5, 2023
 · 
4 min read
Genetown
Odyssey Therapeutics to Present Data for Three Immunology Programs at American College of Rheumatology Convergence 2023
November 9, 2023
 · 
2 min read
Business
Odyssey Therapeutics Appoints Jeremy Sokolove, MD as Chief Medical Officer
October 4, 2023
 · 
3 min read
Business
Odyssey Therapeutics Expands Management Team with Key Appointments in Research Development and Strategy
November 9, 2022
 · 
3 min read
Load More